Orphazyme files for delisting in US
A voluntary delisting of biotech company Orphazyme is expected to come into effect on March 31.
by marketwire, translated by daniel pedersen
Embattled biotech company Orphazyme has filed for a voluntary delisting of its American Depositary Shares (ADS) from Nasdaq Global, a company press release reports on Monday evening.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Orphazyme seeks court protection during restructuring
For subscribers
